- Conditions
- Neoplasm Metastasis, Ureteral Neoplasms, Urinary Bladder Neoplasms
- Interventions
- Digoxin, Midazolam, Pembrolizumab, Rosuvastatin, Trastuzumab Deruxtecan, Vepugratinib, enfortumab vedotin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 677 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,308
matching trials from the local directory fallback.
- Conditions
- Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Orange, California • Sacramento, California
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 640
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 341
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 742
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more
- Conditions
- Hypotension and Shock, Hypoxemic Respiratory Failure, Pulmonary Hypertension of the Newborn (PPHN)
- Interventions
- Dopamine administration, Norepinephrine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- Up to 28 Days
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Headache, SAH (Subarachnoid Hemorrhage)
- Interventions
- Transnasal sphenopalatine ganglion block
- Combination Product
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Positron Emission Tomography
- Interventions
- 18F-DPA-714, 18F-FDG
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Asplenia
- Interventions
- Pneumovax-23
- Biological
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy, RPE-mediated Maculopathy, Stargardt Disease
- Interventions
- Injection
- Biological
- Lead sponsor
- Cellio Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Palo Alto, California • Sacramento, California
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab
- Biological · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 138
- States / cities
- Berkeley, California • Cameron Park, California • Fremont, California + 108 more
- Conditions
- Chronic Granulomatous Disease (CGD)
- Interventions
- Not listed
- Lead sponsor
- Ensoma
- Industry
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
- Interventions
- Follow-up schedule: pre-operative baseline up to 24-months post-procedure
- Device
- Lead sponsor
- Medtronic Spinal and Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 19 more
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 476
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
- Conditions
- Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
- Interventions
- Placebo, Ripasudil
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Placebo Tablet, Senicapoc
- Other · Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Sacramento, California • Walnut Creek, California
- Conditions
- Bleeding Disorder, Connective Tissue Disorder, Factor IX Deficiency, Factor VIII Deficiency, Hematologic Disorder, Hemophilia, Platelet Disorder, Rare Bleeding Disorder, Sickle Cell Disease, Thalassemia, Thrombophilia, Thrombosis, Von Willebrand Diseases
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more
- Conditions
- Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
- Interventions
- Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2036
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more
- Conditions
- Heart Failure
- Interventions
- Alleviant ALV1 System, Sham-Control
- Device · Other
- Lead sponsor
- Alleviant Medical, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 50 more
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- Low Energy SLT, Standard Energy SLT
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 28
- States / cities
- Laguna Hills, California • Pasadena, California • Sacramento, California + 22 more
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone Acetate 250mg, Apalutamide 60mg Tab, Atezolizumab, Capivasertib, Docetaxel, Niraparib 100mg Oral Capsule, Prednisone 5mg Tab, Tazemetostat Pill
- Drug
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
- Conditions
- Atopic Dermatitis, ITCH
- Interventions
- Roflumilast Cream 0.15%
- Drug
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Castration Resistant Prostatic Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
- Interventions
- Darolutamide, JANX007
- Drug · Biological
- Lead sponsor
- Janux Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Multiple Myeloma (MM)
- Interventions
- Cemsidomide, Elranatamab
- Drug · Biological
- Lead sponsor
- C4 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Sacramento, California • Santa Monica, California + 17 more